An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of...
| Publicado en: | CHEST Vol. 143; no. 5; pp. 1478 - 1480 |
|---|---|
| Autores principales: | , , |
| Formato: | case study Journal Article |
| Publicado: |
American College of Chest Physicians
2013 May
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108012487&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 108012487 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00123692 1G4 jtl: CHEST issn: 00123692 maglogo: N pubinfo: dt: 2013 May vid: 143 iid: 5 pid: 2556 pub: American College of Chest Physicians place: Glenview, Illinois artinfo: ui: 108012487 108012487 NLM23648912 2012107906 10.1378/chest.12-1604 NLM23648912 108012487 ppf: 1478 ppct: 2 formats: tig: atl: An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. aug: au: Wysham, Nicholas G. Sullivan, Donald R. Allada, Gopal affil: Department of Internal Medicine, Oregon Health and Science University, Portland, OR. sug: subj: Cryptococcosis Chemically Induced Cryptococcus Proteins Antagonists and Inhibitors Opportunistic Infections Chemically Induced Pneumonia, Bacterial Chemically Induced Heterocyclic Compounds Adverse Effects Aged Antifungal Agents Therapeutic Use Cryptococcosis Diagnosis Cryptococcosis Drug Therapy Enzyme Inhibitors Adverse Effects Enzyme Inhibitors Pharmacodynamics Enzyme Inhibitors Therapeutic Use Fluconazole Therapeutic Use Immunity, Cellular Drug Effects Lung Microbiology Lung Radiography Male Opportunistic Infections Diagnosis Opportunistic Infections Immunology Pneumonia, Bacterial Diagnosis Pneumonia, Bacterial Drug Therapy Myeloproliferative Disorders Drug Therapy Myeloproliferative Disorders Immunology Heterocyclic Compounds Pharmacodynamics Heterocyclic Compounds Therapeutic Use Tomography, X-Ray Computed Treatment Outcomes Aged: 65+ years Male ab: We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class. pubtype: Academic Journal doctype: case study Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|